Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access Mar 26, 2026 4:52 PM Eastern Daylight Time Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access Share Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc.("Agenus†) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will ...

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First- Line MSS Metastatic Colorectal Cancer Mar 17, 2026 4:40 PM Eastern Daylight Time Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer Share A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc.(Nas ...

分组1 - Agenus reported quarterly earnings of $0.56 per share, significantly beating the Zacks Consensus Estimate of a loss of $1.27 per share, and showing improvement from a loss of $2.04 per share a year ago, resulting in an earnings surprise of +144.27% [1] - The company posted revenues of $34.2 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 17.54%, and up from $26.84 million in the same quarter last year [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and revenue estimates three times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - Agenus shares have declined about 1.3% since the beginning of the year, while the S&P 500 has seen a decline of 3.1% [3] - The current consensus EPS estimate for the upcoming quarter is $1.65 on revenues of $103.3 million, and for the current fiscal year, it is $0.54 on revenues of $213.95 million [7] 分组3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]

Revenue and Financial Performance - Agenus recognized approximately $4.2 million in pre-commercial product revenue for the year ended December 31, 2025, from sales of BOT+BAL through early access pathways [462]. - Non-cash royalty revenue related to the sale of future royalties increased by $7.6 million to approximately $108.6 million for the year ended December 31, 2025, due to increased net sales of GSK's vaccines containing the QS-21 adjuvant [463]. - The accumulated deficit as of December 31, 2025, was $2.18 billion, indicating significant losses since inception [460]. - The company has raised approximately $2.05 billion through various financing methods since inception, including common and preferred stock sales and royalty monetization transactions [481]. - Future cash requirements are estimated at $687.0 million for ongoing clinical trials and regulatory efforts, with $628.0 million already expensed as R&D costs [488]. - Net cash used in operating activities was $77.2 million for the year ended December 31, 2025, a decrease from $158.3 million in 2024, highlighting the company's ongoing cash flow challenges [490]. - Cash and cash equivalents decreased to $3.0 million as of December 31, 2025, down from $40.4 million in 2024, indicating a need for additional capital to support operations [484]. Research and Development - Research and development expenses decreased by 49% to $79.3 million for the year ended December 31, 2025, from $155.5 million for the year ended December 31, 2024 [464]. - Research and development (R&D) expenses totaled $79.3 million for the year ended December 31, 2025, a decrease from $155.5 million in 2024, with significant costs attributed to antibody programs and other R&D initiatives [472]. - The lead clinical program, botensilimab (BOT), received Fast Track designation from the FDA for treating patients with specific types of metastatic colorectal cancer [444]. - Agenus has collaborations with several companies, including Bristol-Myers Squibb and Merck, resulting in over a dozen antibody pre-clinical or clinical development programs [445]. - The company is focused on developing its saponin-based vaccine adjuvant platform, particularly the next-generation cultured plant cell QS-21 [455]. Expenses and Losses - General and administrative (G&A) expenses decreased by 24% to $54.4 million for the year ended December 31, 2025, down from $71.9 million in 2024, primarily due to a $9.1 million decrease in personnel-related expenses [466]. - Non-operating expenses increased by $8.1 million, resulting in a net expense of $2.2 million for the year ended December 31, 2025, compared to income of $5.8 million in 2024, mainly due to a $3.5 million loss on the deconsolidation of a foreign subsidiary [467]. - The company has incurred significant losses and is likely to continue doing so until it becomes a commercial entity generating profits [460]. - The accumulated deficit reached $2.18 billion as of December 31, 2025, with expectations of continued significant losses in the coming years as the company advances its technologies and product candidates [481]. Debt and Liabilities - Long-term debt amounts to $36.764 billion, with no payments due in the 1-3 years, 3-5 years, or beyond 5 years [492]. - Operating leases total $16.897 billion, with $2.396 billion due within 1 year, $4.897 billion in 1-3 years, $4.505 billion in 3-5 years, and $5.099 billion beyond 5 years [492]. - Finance leases are recorded at $127 million, with $110 million due within 1 year and $17 million in 1-3 years [492]. Currency and Interest Rate Exposure - Approximately 4.7% of cash used in operations for the year ended December 31, 2025, was from foreign subsidiaries, indicating exposure to foreign currency exchange rate fluctuations [501]. - The company does not currently employ specific strategies to manage foreign currency exchange rate risks, such as derivatives or hedging [501]. - The investment policy aims to preserve principal, maintain liquidity, and maximize yields, prohibiting investments in structured vehicles and asset-backed commercial paper [503]. - The company is exposed to fluctuations in interest rates as it seeks debt financing and invests excess cash [502]. - Non-cash interest expense related to royalty financing transactions is recorded based on estimated royalty payments, which may vary due to several factors [497]. - The company periodically assesses expected royalty payments using historical results and market forecasts, adjusting amortization of liabilities as necessary [498]. Other Significant Events - Incyte has terminated the OX40 program and intends to terminate the entire collaboration agreement by February 2026, reverting rights back to Agenus [446]. - The gain from the deconsolidation of MiNK Therapeutics, Inc. was $100.9 million for the year ended December 31, 2025, reflecting the loss of control in Q3 2025 [468]. - Interest expense decreased to $55.3 million for the year ended December 31, 2025, from $117.6 million in 2024, mainly due to reduced non-cash interest related to the Royalty Purchase Agreement [470].

Revenue and Financial Performance - Agenus recognized approximately $4.2 million in net revenue from early access programs in 2025, with $3.2 million in the fourth quarter alone[18]. - The company reported an operating loss of $20.2 million for the full year 2025[18]. Clinical Trials and Research - The BOT+BAL program achieved a 42% two-year overall survival rate and a median overall survival of approximately 21 months in heavily pretreated MSS mCRC patients[11]. - The BATTMAN Phase 3 registrational trial for BOT+BAL has been initiated, aiming to enroll approximately 830 patients across more than 100 sites in multiple countries[15][21]. - Clinical data from over 1,200 patients across nine tumor types support the potential of BOT+BAL as a next-generation immunotherapy[10][28]. Strategic Collaborations and Partnerships - A strategic collaboration with Zydus Lifesciences provided $91 million in upfront capital to strengthen Agenus' balance sheet and manufacturing capacity[16]. - The collaboration with Zydus includes a $20 million contingent payment triggered by initial BOT+BAL work orders[17]. Program Expansion and Global Reach - The early access programs have expanded globally, with over 200 physician inquiries from more than 30 countries[5][9]. - France's AAC program has expanded to include additional cancers, enhancing patient access to BOT+BAL[7]. Regulatory and Commercial Strategy - Agenus aims to advance regulatory filings in the U.S. and EU while strengthening its commercial readiness[23].

Core Insights - The article discusses the recent financial performance of a leading technology company, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $50 billion for the last quarter, representing a 20% increase year-over-year [1] - Net income reached $10 billion, which is a 25% increase compared to the same quarter last year [1] - Earnings per share (EPS) rose to $5, up from $4 in the previous year, indicating strong profitability [1] Market Position - The company has strengthened its market position, capturing an additional 5% market share in the technology sector [1] - Increased demand for its cloud services has been a key driver of growth, contributing to 30% of total revenue [1] Future Outlook - The company expects continued growth, projecting a revenue increase of 15% for the next quarter [1] - Investments in research and development are anticipated to enhance product offerings and drive further market expansion [1]

Core Insights - Agenus Inc. has triggered a $20 million contingent payment under its strategic collaboration with Zydus Lifesciences Ltd. [1] - The payment is linked to contracted work orders for critical chemistry, manufacturing, and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL) [1] Company Summary - Agenus Inc. is recognized as a leader in immuno-oncology innovation [1] - The collaboration with Zydus Lifesciences is focused on advancing the development of botensilimab and balstilimab [1]

Core Viewpoint - Agenus Inc. is set to release its fourth quarter and year-end 2025 financial results on March 16, 2026, before market opening, indicating a focus on transparency and stakeholder engagement [1] Financial Results Announcement - The financial results will be disclosed before the market opens on March 16, 2026, highlighting the company's commitment to timely reporting [1] - A stakeholder briefing webcast will be held in late March to discuss strategic plans and data milestones [1] Development Programs - The company will provide updates on the global development programs for botensilimab (BOT) and balstilimab (BAL), which are key components of its immuno-oncology portfolio [1]

Core Insights - Agenus presented new biomarker data demonstrating survival stratification in microsatellite-stable metastatic colorectal cancer (MSS mCRC) and other immunologically cold tumors treated with the combination of botensilimab (BOT) and balstilimab (BAL) [1] Group 1: Clinical Trial Findings - The Phase 1b C-800-01 trial evaluated BOT in combination with BAL, showing that survival outcomes are influenced by systemic inflammation and tumor immune activity [1] - In 341 efficacy-evaluable patients, the 24-month overall survival rate was 38%, with a median overall survival of 17.2 months, a clinical benefit rate of 26%, and an objective response rate of 17% [1] - Clinical activity was observed across various tumor types, including MSS mCRC, ovarian cancer, sarcoma, and non-small cell lung cancer, with durable benefits noted in patients both naïve to and resistant to prior therapies [1] Group 2: Biomarker Insights - The integration of blood and tumor biomarkers improved survival stratification in MSS mCRC, identifying distinct patient subgroups with different survival outcomes, achieving a C-index of up to 0.73 [1] - Patients experiencing immune-mediated adverse events (imAEs) within the first 12 weeks of treatment had a longer median overall survival of 22.4 months compared to 13.7 months for those without imAEs [1] - Elevated systemic inflammation markers, such as the neutrophil-to-lymphocyte ratio and C-reactive protein, were significantly associated with shorter overall survival [1] Group 3: Mechanism of Action - Botensilimab is designed to enhance both innate and adaptive anti-tumor immune responses, potentially extending immunotherapy benefits to cold tumors that typically respond poorly to standard treatments [2] - The Fc-enhanced mechanism of BOT allows for clinical benefits even at low levels of immune infiltration, suggesting a lower threshold of baseline immunity is required for activity [1] - Approximately 1,200 patients have been treated with BOT and/or BAL in clinical trials, demonstrating clinical responses across nine metastatic, late-line cancers [2]

Core Insights - Agenus Inc. announced new data from its botensilimab (BOT) immunotherapy program will be presented at the AACR-IO Conference, focusing on systemic and tumor inflammation biomarkers in immunologically cold tumors [1] Group 1: Presentation Details - The poster presentation titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab" will evaluate the association of systemic inflammatory markers and tumor microenvironment immune activity with clinical outcomes [1] - The presentation will take place on February 19, 2026, from 12:15 PM to 3:15 PM PT at the JW Marriott, Platinum Ballroom [1] Group 2: About Botensilimab and Balstilimab - Botensilimab is designed to enhance both innate and adaptive anti-tumor immune responses, particularly in "cold" tumors that typically respond poorly to standard therapies [1] - Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in clinical trials, showing clinical responses across nine metastatic, late-line cancers [1] - Balstilimab is a fully human monoclonal antibody that blocks PD-1 from interacting with its ligands, having been evaluated in over 900 patients with a favorable tolerability profile [1] Group 3: Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994, aiming to expand patient populations benefiting from cancer immunotherapy [1] - The company has robust development capabilities, including commercial and clinical cGMP manufacturing facilities, research, and global clinical operations [1]